These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 8809195

  • 1. Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model.
    Sato N, Gleave ME, Bruchovsky N, Rennie PS, Goldenberg SL, Lange PH, Sullivan LD.
    J Steroid Biochem Mol Biol; 1996 May; 58(2):139-46. PubMed ID: 8809195
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Butyrate analogue, isobutyramide, inhibits tumor growth and time to androgen-independent progression in the human prostate LNCaP tumor model.
    Gleave ME, Sato N, Sadar M, Yago V, Bruchovsky N, Sullivan L.
    J Cell Biochem; 1998 Jun 01; 69(3):271-81. PubMed ID: 9581866
    [Abstract] [Full Text] [Related]

  • 4. Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer.
    Thalmann GN, Sikes RA, Chang SM, Johnston DA, von Eschenbach AC, Chung LW.
    J Natl Cancer Inst; 1996 Jun 19; 88(12):794-801. PubMed ID: 8637045
    [Abstract] [Full Text] [Related]

  • 5. Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors.
    Gleave ME, Hsieh JT, Wu HC, von Eschenbach AC, Chung LW.
    Cancer Res; 1992 Mar 15; 52(6):1598-605. PubMed ID: 1371718
    [Abstract] [Full Text] [Related]

  • 6. Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence.
    Ettinger SL, Sobel R, Whitmore TG, Akbari M, Bradley DR, Gleave ME, Nelson CC.
    Cancer Res; 2004 Mar 15; 64(6):2212-21. PubMed ID: 15026365
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.
    Jin RJ, Wang Y, Masumori N, Ishii K, Tsukamoto T, Shappell SB, Hayward SW, Kasper S, Matusik RJ.
    Cancer Res; 2004 Aug 01; 64(15):5489-95. PubMed ID: 15289359
    [Abstract] [Full Text] [Related]

  • 14. Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines.
    Spitzweg C, Zhang S, Bergert ER, Castro MR, McIver B, Heufelder AE, Tindall DJ, Young CY, Morris JC.
    Cancer Res; 1999 May 01; 59(9):2136-41. PubMed ID: 10232600
    [Abstract] [Full Text] [Related]

  • 15. Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen.
    Akakura K, Bruchovsky N, Goldenberg SL, Rennie PS, Buckley AR, Sullivan LD.
    Cancer; 1993 May 01; 71(9):2782-90. PubMed ID: 7682149
    [Abstract] [Full Text] [Related]

  • 16. Manipulating prohibitin levels provides evidence for an in vivo role in androgen regulation of prostate tumours.
    Dart DA, Spencer-Dene B, Gamble SC, Waxman J, Bevan CL.
    Endocr Relat Cancer; 2009 Dec 01; 16(4):1157-69. PubMed ID: 19635783
    [Abstract] [Full Text] [Related]

  • 17. Establishment and characterization of androgen-independent human prostate cancer LNCaP cell model.
    Igawa T, Lin FF, Lee MS, Karan D, Batra SK, Lin MF.
    Prostate; 2002 Mar 01; 50(4):222-35. PubMed ID: 11870800
    [Abstract] [Full Text] [Related]

  • 18. Differential effects of naturally occurring and synthetic organoselenium compounds on biomarkers in androgen responsive and androgen independent human prostate carcinoma cells.
    Pinto JT, Sinha R, Papp K, Facompre ND, Desai D, El-Bayoumy K.
    Int J Cancer; 2007 Apr 01; 120(7):1410-7. PubMed ID: 17205524
    [Abstract] [Full Text] [Related]

  • 19. Androgen causes growth suppression and reversion of androgen-independent prostate cancer xenografts to an androgen-stimulated phenotype in athymic mice.
    Chuu CP, Hiipakka RA, Fukuchi J, Kokontis JM, Liao S.
    Cancer Res; 2005 Mar 15; 65(6):2082-4. PubMed ID: 15781616
    [Abstract] [Full Text] [Related]

  • 20. Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells.
    Sadar MD, Gleave ME.
    Cancer Res; 2000 Oct 15; 60(20):5825-31. PubMed ID: 11059779
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.